Disease · HP_0002153
Hyperkalemia
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Hyperkalemia. Diseases, record HP_0002153. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002153
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Hyperkalemia
- Open Targets ID
- HP_0002153
- Other names
Elevated potassium(1+) concentration, Elevated potassium(1+) level, Elevated potassium(1+) level in blood, Increased circulating potassium concentration, Increased potassium(1+) concentration, Increased potassium(1+) level, Increased potassium(1+) level in blood
- Highest stage of its drugs
- Approval, for 5 of its 14 drugs, from DailyMed, EMA Human Drugs, FDA and TTD
Source Open Targets
Drugs14
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| SODIUM ZIRCONIUM CYCLOSILICATE | CHEMBL3301592 | Small molecule | Approval | DailyMed, EMA Human Drugs, FDA and TTD | 24 | 19 | 19 | Drugs and targets |
| PATIROMER | CHEMBL2107875 | Small molecule | Approval | EMA Human Drugs | 18 | 17 | 17 | Drugs and targets |
| SODIUM POLYSTYRENE SULFONATE | CHEMBL1201484 | Small molecule | Approval | DailyMed | 3 | 2 | 2 | Drugs and targets |
| PATIROMER CALCIUM | CHEMBL2107840 | Small molecule | Approval | FDA and TTD | 2 | 0 | 0 | Drugs and targets |
| PATIROMER SORBITEX CALCIUM | CHEMBL5315081 | Small molecule | Approval | FDA | 1 | 0 | 0 | Drugs and targets |
| LOSARTAN | CHEMBL191 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| SPIRONOLACTONE | CHEMBL1393 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TENAPANOR | CHEMBL3304485 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| ALBUTEROL | CHEMBL714 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CANDESARTAN | CHEMBL1016 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
1 to 10 of 14
See all 14 drugsTargets5
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| AGTR1 | Type-1 angiotensin II receptor | 5 | Type-1 angiotensin II receptor antagonist | Phase 2 | https://conductscience.org/library/genes/185 | Drugs and targets |
| ADRB2 | Beta-2 adrenergic receptor | 1 | Beta-2 adrenergic receptor agonist | Unknown | https://conductscience.org/library/genes/154 | Drugs and targets |
| INSR | Insulin receptor | 1 | Insulin receptor agonist | Unknown | https://conductscience.org/library/genes/3643 | Drugs and targets |
| NR3C2 | Mineralocorticoid receptor | 1 | Mineralocorticoid receptor antagonist | Phase 2 | https://conductscience.org/library/genes/4306 | Drugs and targets |
| SLC9A3 | Sodium/hydrogen exchanger 3 | 1 | Sodium/hydrogen exchanger 3 inhibitor | Phase 2 | https://conductscience.org/library/genes/6550 | Drugs and targets |
Trials38
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03888066 | Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND) | Phase 3 | 1,195 | 2023-02-24 | Hyperkalemia | PATIROMER | Its record names the disease | ClinicalTrials.gov |
| NCT01737697 | Safety & Efficacy of Zirconium Silicate in Mild to Moderate Hyperkalemia | Phase 3 | 754 | 2018-10-12 | Hyperkalemia | SODIUM ZIRCONIUM CYCLOSILICATE | Its record names the disease | ClinicalTrials.gov |
| NCT02163499 | Open-label Safety and Efficacy of Sodium Zirconium Cyclosilicate for up to 12 Months | Phase 3 | 751 | 2018-06-27 | Hyperkalemia | SODIUM ZIRCONIUM CYCLOSILICATE | Its record names the disease | ClinicalTrials.gov |
| NCT01371747 | Patiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN) | Phase 2 | 324 | 2015-12-17 | Chronic Kidney Disease, Hypertension, Hyperkalemia | LOSARTAN, PATIROMER, SPIRONOLACTONE | Its record names the disease | ClinicalTrials.gov |
| NCT03528681 | A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia. | Phase 3 | 270 | 2025-05-14 | Hyperkalemia | SODIUM ZIRCONIUM CYCLOSILICATE | Its record names the disease | ClinicalTrials.gov |
| NCT02875834 | A Study to Investigate the Safety and Efficacy of ZS in Patients With Hyperkalemia | Phase 3 | 267 | 2020-08-19 | Hyperkalemia | SODIUM ZIRCONIUM CYCLOSILICATE | Its record names the disease | ClinicalTrials.gov |
| NCT02088073 | Safety & Efficacy of Zirconium Silicate Dosed for 28 Days in Hyperkalemia. | Phase 3 | 258 | 2018-12-07 | Hyperkalemia | SODIUM ZIRCONIUM CYCLOSILICATE | Its record names the disease | ClinicalTrials.gov |
| NCT01810939 | A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) | Phase 3 | 243 | 2015-12-15 | Chronic Kidney Disease (CKD), Hyperkalemia (HK) | PATIROMER | Its record names the disease | ClinicalTrials.gov |
| NCT03303521 | A Study to Test Whether ZS (Sodium Zirconium Cyclosilicate) Can Reduce the Incidence of Increased Blood Potassium Levels Among Dialized Patients. | Phase 3 | 196 | 2020-02-20 | Hyperkalemia | SODIUM ZIRCONIUM CYCLOSILICATE | Its record names the disease | ClinicalTrials.gov |
| NCT03172702 | Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia | Phase 3 | 150 | 2020-05-01 | Hyperkalemia | SODIUM ZIRCONIUM CYCLOSILICATE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 38
See all 38 trialsComparisons in its trials19
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Acute Phase: ZS vs Extended Dosing Phase: ZS: deaths from any cause | 0 of 751 | 8 of 746 | 1,497 | NCT02163499 | Trial comparisons |
| Acute Phase: ZS vs Extended Dosing Phase: ZS: serious adverse events | 1 of 751 | 161 of 746 | 1,497 | NCT02163499 | Trial comparisons |
| Patiromer vs Placebo: deaths from any cause | 24 of 439 | 18 of 439 | 878 | NCT03888066 | Trial comparisons |
| Patiromer vs Placebo: serious adverse events | 54 of 439 | 58 of 439 | 878 | NCT03888066 | Trial comparisons |
| Correction Phase vs Maintenance Phase: deaths from any cause | 0 of 150 | 2 of 150 | 300 | NCT03172702 | Trial comparisons |
| Correction Phase vs Maintenance Phase: serious adverse events | 1 of 150 | 27 of 150 | 300 | NCT03172702 | Trial comparisons |
| Sodium Zirconium Cyclosilicate (SZC) vs Placebo: deaths from any cause | 1 of 96 | 0 of 99 | 195 | NCT03303521 | Trial comparisons |
| Sodium Zirconium Cyclosilicate (SZC) vs Placebo: serious adverse events | 7 of 96 | 8 of 99 | 195 | NCT03303521 | Trial comparisons |
| Group 1 - Dosing Without Food vs Group 2 - Dosing With Food: deaths from any cause | 1 of 57 | 0 of 56 | 113 | NCT02694744 | Trial comparisons |
| Group 1 - Dosing Without Food vs Group 2 - Dosing With Food: serious adverse events | 4 of 57 | 1 of 56 | 113 | NCT02694744 | Trial comparisons |
1 to 10 of 19
See all 19 comparisons in its trialsPapers from its trials27
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 32750456 | RESULT | 1 | PubMed |
| 28993507 | RESULT | 1 | PubMed |
| 41957746 | DERIVED | 1 | PubMed |
| 41730555 | DERIVED | 1 | PubMed |
| 41565838 | DERIVED | 1 | PubMed |
| 40329202 | DERIVED | 1 | PubMed |
| 39969301 | DERIVED | 1 | PubMed |
| 39340493 | DERIVED | 1 | PubMed |
| 39159624 | DERIVED | 1 | PubMed |
| 39112102 | DERIVED | 1 | PubMed |
1 to 10 of 27
See all 27 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0002153
GET https://conductscience.org/api/diseases/v1/HP_0002153/trials?page=2